NCAM1 and neuroblastoma: Moreover, lorvotuzumab mertansine (IMGN901), an immunoconjugate consisting of the humanized mouse anti-NCAM huN-901 mAb conjugated to an anti-tubulin agent, was tested in a phase II clinical trial in relapsed or refractory childhood tumors including NB; however, limited clinical activity was reported [177].